[Current role of intracavernous therapy in the treatment of erectile dysfunction].
Asuar Aydillo
Simón
S
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000527:Alprostadil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005355:Fibrosis; D006801:Humans; D007267:Injections; D008297:Male; D010208:Papaverine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010342:Patient Acceptance of Health Care; D010410:Penile Erection / Q000187:drug effects*; D010413:Penis / Q000473:pathology; D010643:Phenoxybenzamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010646:Phentolamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies; D012646:Self Administration; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D004338:Drug Combinations; D014665:Vasodilator Agents; D010643:Phenoxybenzamine; D010208:Papaverine; D000527:Alprostadil; D010646:Phentolamine